FDA approves new treatment for rare liver disorder

FOSTER CITY, Calif. - The U.S. Food and Drug Administration (FDA) has approved LIVMARLI® (maralixibat) oral solution for the treatment of cholestatic pruritus in patients aged five years and older with progressive familial intrahepatic cholestasis (PFIC), Mirum Pharmaceuticals (NASDAQ:MIRM) announced today. The approval, based on the Phase 3 MARCH study, signifies a statistically significant reduction...

Read More

Crown Castle co-founder proposes operational overhaul

HOUSTON - Ted B. Miller, co-founder of Crown Castle Inc. (NYSE: NYSE:CCI) and his investment firm Boots Capital Management, LLC, has publicly addressed the Crown Castle Board of Directors, advocating for significant operational changes to enhance shareholder value. This move follows recent scrutiny by Elliott Investment Management L.P. and a court\'s recognition of \"colorable claims\"...

Read More